I-Mab (IMAB) announced its new business model, focused on its global capabilities built to accelerate access to medicines and to enable broad strategic growth. The company announced its intention to pursue a Hong Kong IPO through dual listing on Nasdaq and Hong Kong Stock Exchange. The company intends to operate under the new name of NovaBridge Biosciences.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMAB:
- I MAB (ADS) trading halted, news pending
- I-Mab Reports H1 2025 Financial Results Amid Strategic Shift
- I-Mab initiated with an Outperform at Leerink
- I-Mab to Vote on Name Change to NovaBridge Biosciences
- Trump Trade: Offshore wind seen with no future in the U.S. under Trump